While often the antiviral of choice among high-risk patients, a new study found nearly 15 percent of 62,525 hospitalized COVID-19 patients had a medical contraindication to Paxlovid’s antiviral combination of nirmatrelvir and ritonavir.
Read the full post on Becker's Hospital Review - Healthcare News
